Skip to content
    MET
    Earnings call· Jun 2026(Q2 FY26)

    METLIFE Q2 FY26 earnings call MET

    Aug 6, 2026 Source

    Executive summary

    MetLife Q2 FY26 — Strong Earnings Growth and Capital Returns

    MetLife delivered a strong second quarter, showcasing the effectiveness of its 'New Frontier' strategy with balanced growth across capital-light and capital-driven earnings engines. The company achieved robust profitability and sales momentum, supported by disciplined expense management and strategic AI adoption. Management remains focused on prudent capital deployment, including significant shareholder returns, while navigating a lumpy PRT market and evolving mortality trends.

    Highlights

    5

    • Adjusted earnings increased 15% year-over-year to $1.6 billion, with adjusted EPS up 20% to $2.43.

    • Adjusted return on equity (ROE) reached 17%, hitting the top end of the 15% to 17% annual target range.

    • Direct expense ratio was 12.1%, in line with the full-year target, despite a ~50 basis point impact from the PineBridge acquisition.

    • Sales rose 7% year-over-year, driven by strong growth across international businesses.

    • A new $3 billion share repurchase authorization was announced, reflecting confidence in capital generation.

    Concerns

    3

    • RIS total investment spread was 97 basis points, below the guidance range of 100 to 120 basis points, primarily due to weaker private equity returns.

    • Corporate & Other reported an adjusted loss of $160 million, compared to a loss of $142 million a year ago.

    • MetLife Investment Management (MIM) adjusted earnings are expected to be towards the low end of its $240 million to $280 million full-year guidance range.

    Guidance & targets

    10
    CategoryTargetConfidence
    Adjusted Return on Equity (ROE)
    15% to 17%
    high materiality
    High
    Direct Expense Ratio
    12.1%
    medium materiality
    High
    MetLife Investment Management (MIM) Adjusted Earnings
    $240 million to $280 million (towards low end)
    medium materiality
    Medium
    Japan Economic Solvency Ratio (ESR)
    Top end of 170% to 190% range
    medium materiality
    High
    Retained Liability Exposures Growth (RIS)
    3% to 5%
    medium materiality
    High
    Group Life Mortality Ratio
    83% to 88%
    medium materiality
    High
    Non-Medical Health Interest-Adjusted Benefit Ratio
    70% to 75%
    medium materiality
    High
    Cash and Liquid Assets at Holding Companies
    $3 billion to $4 billion
    medium materiality
    High
    Total Investment Spread (RIS)
    100 to 120 basis points
    medium materiality
    Medium
    Core Investment Spread (RIS, ex-VII)
    95% to 100%
    medium materiality
    High

    Segment performance

    7
    SegmentRevenueYoYQoQMargin
    Group Benefits
    Outstanding quarter driven by favorable underwriting margins and volume growth. Mortality trends improved, and non-medical health benefit ratio was within target. Strong sales momentum across various product lines and market segments.
    Group Life mortality ratio: 79% (better than 83%-88% target range)Non-medical health interest-adjusted benefit ratio: 73.9% (within 70%-75% target range)Adjusted PFOs: up 1% YoY (up 4% excluding participating contracts)Year-to-date sales: up 9%Regional business sales: up 11% (led by under-1,000 employee market)Disability and voluntary products sales: double-digit gains YTD
    		—25%—$503 million (adjusted earnings)
    Retirement and Income Solutions (RIS)
    Adjusted earnings growth driven by favorable recurring interest margins and volume growth, partially offset by lower variable investment income. The segment continues to benefit from its origination platform and diversification into areas like UK funded reinsurance.
    Adjusted PFOs (excluding pension risk transfers): up 19% (driven by UK longevity reinsurance and structured settlements)Total investment spread: 97 bps (below 100-120 bps guidance range)Core spread (excluding VII): 100 bps (up 5 bps sequentially)Retained liability exposures growth: 3% YoY (low end of 2026 outlook range)
    		—2%—$377 million (adjusted earnings)
    Asia
    Strong results reflecting favorable equity markets, higher variable investment income, and continued volume growth. Sales momentum was broad-based, with a balanced mix of U.S. dollar and yen product sales.
    Adjusted earnings (constant currency): up 25%Sales (constant currency): up 17% (fueled by equity market tailwinds in Korea and new medical product in Japan)General Account assets under management (amortized cost, constant currency): up 6%Japan sales: up 2% YoY (13% sequentially), with almost 90% A&H growth (constant currency)
    		—21%—$420 million (adjusted earnings)
    Latin America
    Record quarterly adjusted earnings driven by strong volume growth and favorable market factors, partially offset by the Mexico VAT change. Growth was broad-based across Brazil, Mexico, and Chile.
    Adjusted earnings (constant currency): up 4%Adjusted PFOs: up 16% (6% constant currency)Sales (constant currency): up 9%Encaje return: 5.6% (Q2)Brazil sales contribution to LatAm: 20%
    		—15%—$268 million (adjusted earnings)
    EMEA
    Results driven by strong volume growth, partially offset by higher expenses. Sustained sales momentum and solid renewal activity contributed to top-line strength and durable earnings power.
    Adjusted earnings (constant currency): up 11%Adjusted PFOs (constant currency): up 12%Sales (constant currency): up 15%
    		—8%—$108 million (adjusted earnings)
    MetLife Investment Management (MIM)
    Growth reflected the contribution from integrating PineBridge Investments and expense management. Momentum is building, with integration benefits expected to drive upward earnings trajectory in H2.
    Other revenues: up 34%Total assets under management (AUM): $748 billion (up $12 billion sequentially)Institutional client AUM: up $7 billionOperating margin improvement: 410 bps
    		—6%—$57 million (adjusted earnings)
    Corporate & Other
    The adjusted loss increased from $142 million a year ago, primarily due to foregone earnings from prior year strategic reinsurance transactions and market-related employee costs, partly offset by favorable life underwriting margins.
    		———($160 million) (adjusted loss)

    Operational metrics

    17
    Adjusted Earnings
    $1.6 billionup 15% YoY
    Q2 FY26

    Company-wide adjusted earnings.

    Adjusted EPS
    $2.43up 20% YoY
    Q2 FY26

    Adjusted earnings per share.

    Adjusted Premiums, Fees and Other Revenues (ex-PRT)
    5%YoY
    Q2 FY26

    Company-wide revenue growth excluding pension risk transfers.

    Sales Growth
    7%YoY
    Q2 FY26

    Company-wide sales growth, led by international businesses.

    Variable Investment Income (pretax)
    $231 million
    Q2 FY26

    Pretax variable investment income.

    Direct Expense Ratio
    12.1%vs 11.7% FY25 and Q2 FY25
    Q2 FY26

    Expense ratio, managed on a full-year basis, on track to beat 2026 target.

    Share Repurchases
    $700 million
    Q2 FY26

    Amount of common shares repurchased during the quarter.

    Capital Returned to Shareholders
    $2.4 billion
    YTD through July

    Total capital returned through stock buybacks and common dividends.

    Cash and Liquid Assets at Holding Companies
    $3.4 billion
    June 30, 2026

    Within the target buffer of $3 billion to $4 billion.

    Effective Tax Rate on Adjusted Earnings
    23%below 24%-26% guidance range
    Q2 FY26

    The company's effective tax rate for the quarter.

    Private Equity Returns
    0.8%
    Q1 FY26 (reported on 1-quarter lag)

    Average return for private equity investments, contributing to lower variable investment income.

    Real Estate and Other Funds Returns
    1.1%
    Q1 FY26 (reported on 1-quarter lag)

    Average return for real estate and other funds.

    UK Funded Reinsurance Written
    >$1 billion
    YTD

    Amount of UK funded reinsurance written year-to-date, contributing to RIS growth.

    Latin America Earnings Path
    $1 billiondouble pre-pandemic levels
    FY26

    Latin America is on track to generate $1 billion in earnings for the full year.

    Brazil Sales Contribution to LatAm
    20%
    Q2 FY26

    Brazil is the fastest-growing life insurer in that market and contributes significantly to overall Latin America sales.

    New Share Repurchase Authorization
    $3 billion
    Ongoing

    New share repurchase authorization announced.

    Share Repurchases (July)
    $225 million
    July 2026

    Additional shares repurchased in July.

    Industry KPIs

    8
    MetricValueDetails
    Capital returns$2.4 billionUSD
    ROE operating ROE17%%
    Net investment income$231 millionUSD
    Retention persistencyHigher
    Life specific when present—
    Net premiums written earned5%%
    Statutory regulatory capital$16.4 billionUSD
    Prior year reserve development2 pointspoints

    Product announcements

    2
    ProductTypeDetails
    Identity Theft Productexpansion
    Medical Productlaunch

    Deals & partnerships

    1
    PineBridge InvestmentsIntegration of PineBridge Investments into MetLife Investment Management (MIM).

    The integration of PineBridge Investments is contributing to MIM's adjusted earnings growth and is a factor in the direct expense ratio.

    Risks & headwinds

    7
    Weaker Private Equity ReturnsQ2 FY26

    0.8% average return for Q1 FY26 (reported on lag)

    Mitigation: Management expects stronger private equity returns in Q3, particularly from venture capital investments, supported by elevated IPO activity and higher public market valuations.

    Mexico VAT ChangeQ2 FY26

    Impact on Latin America earnings

    Mitigation: Partially offset by strong volume growth and favorable market factors, including an elevated Encaje return of 5.6%.

    Higher ExpensesQ2 FY26

    Partially offset EMEA segment growth

    Mitigation: Strong volume growth and ongoing sales momentum in EMEA helped mitigate the impact.

    Foregone Earnings from Prior Strategic Reinsurance TransactionsQ2 FY26

    Contributed to $160 million adjusted loss in Corporate & Other

    Mitigation: Partly offset by favorable life underwriting margins.

    Lumpy Jumbo PRT MarketH1 FY26

    Lighter activity in H1 FY26

    Mitigation: Stronger pipeline for H2 FY26; diversification into UK funded reinsurance (>$1 billion written YTD).

    Yen VolatilityRecent

    Market volatility

    Mitigation: MetLife's diversified distribution, product innovation (USD and local currency products), and execution excellence in Japan help sustain sales momentum.

    Modest Decline in Private Equity AllocationMulti-year journey

    Distributions expected to outpace contributions

    Mitigation: Still investing in the space, but strategic shift due to higher rate environment.

    What to watch in Q3 FY26

    5

    Group Life Mortality Ratio

    H2 FY26
    Current79%
    TargetNormalization towards 83%-88% target range

    Why it matters

    The Q2 ratio was significantly better than target, but management expects 2 points of favorability to normalize, impacting future underwriting results.

    Now this quarter, in particular, we saw about 2 points of favorability that came from a combination of prior period development as well as below expectations in terms of severity of claims. So think about those 2 points as being we expect those to normalize as we go forward.

    Q&A highlights

    7

    What areas of the company would be potential targets for inorganic additions, given the mention of M&A in prepared remarks?

    MetLife's M&A philosophy remains unchanged, focusing on strategic capabilities. Likely areas for consideration are asset management (adjacencies/complementary capabilities) and group benefits (new capabilities/solutions, though no current product gaps). The company maintains a high bar for M&A, comparing it to other capital uses.

    “The more likely area I would say is asset management, and you saw us do the PineBridge Investments deal late last year. And again, here, I would sort of emphasize that we'd be looking at adjacencies or a complementary capabilities as opposed to anything transformational.”

    asked by Ryan Krueger · answered by Michel Khalaf

    2 min read6 chapters

    Detailed Narrative

    01

    New Frontier Strategy and Earnings Engines

    MetLife's 'New Frontier' strategy leverages two complementary earnings engines: capital-light businesses (Group Benefits, Latin America, EMEA, asset management) generating fee and underwriting income, and capital-driven businesses (retirement, spread-based) utilizing origination and risk management. These engines reinforce each other, with capital-driven businesses originating assets managed by MetLife Investment Management, supporting capital-light growth. This balanced approach contributes to a more resilient company performance across various market conditions.

    02

    AI Adoption and Productivity Gains

    MetLife views AI as a structural advantage, leveraging its scale and vast data volumes from new policies, service interactions, and claims to enhance growth and productivity. The company rigorously monitors AI-related investments and expenses, ensuring they meet return standards. The gains in growth, productivity, and customer service are reported to far exceed the costs, with strong governance and risk oversight central to AI deployment.

    03

    PRT Market Dynamics and Diversification

    The Pension Risk Transfer (PRT) market, particularly the jumbo segment, is characterized as lumpy, making quarter-to-quarter or even year-to-year activity difficult to predict📌. While the first half of FY26 was lighter for jumbo PRTs, a stronger pipeline is anticipated for the second half. MetLife is also diversifying its growth by leveraging existing capabilities, such as writing over $1 billion in UK funded reinsurance year-to-date, which contributes to overall RIS growth.

    04

    Mortality Trends and Underwriting Experience

    Mortality trends are generally returning to pre-COVID levels, with more pronounced improvements observed in the working-age population compared to the retiree and older populations. Group Life experienced 2 points of favorability from prior period development and lower claim severity, though this is expected to normalize📎. In RIS, the older population's mortality experience is largely in line with expectations and reserves, reflecting appropriate pricing and reserving.

    05

    Private Equity Allocation Strategy

    MetLife is pursuing a multi-year strategy of a modest decline in its private equity allocation. This is driven by the current higher interest rate environment, where distributions from the seasoned portfolio are expected to outpace new contributions. The company remains opportunistic in its investments within the space, but the overall direction is a gradual reduction in PE exposure.

    06

    Japan Market Performance and Strategy

    Despite market volatility🌐, including yen fluctuations, MetLife's sales in Japan and across Asia have shown strong momentum, with Q2 sales up 17% constant currency. This success is attributed to the company's scale, diversified distribution channels, product innovation (including both USD and local currency products), and strong execution. The balanced product mix helps mitigate reliance on any single product or currency.

    AI-generated summary of the company’s earnings call. Not investment advice.